

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/224865 A1

(51) International Patent Classification:

C07D 211/46 (2006.01) C07D 401/06 (2006.01)
A61K 31/445 (2006.01) C07D 401/10 (2006.01)
A61K 31/4525 (2006.01) C07D 401/14 (2006.01)
A61K 31/453 (2006.01) C07D 405/06 (2006.01)
A61K 31/4535 (2006.01) C07D 405/10 (2006.01)
A61K 31/4545 (2006.01) C07D 409/06 (2006.01)
A61K 31/506 (2006.01) C07D 409/14 (2006.01)
A61P 1/16 (2006.01) C07D 413/14 (2006.01)
A61P 25/00 (2006.01) C07D 417/14 (2006.01)
A61P 3/00 (2006.01)

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2021/053864

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

06 May 2021 (06.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/021,432 07 May 2020 (07.05.2020) US

(71) Applicant: **ALECTOS THERAPEUTICS INC.**
[CA/CA]; 8999 Nelson Way, Burnaby, British Columbia
V5A 4B5 (CA).

(72) Inventors: **KAUL, Ramesh**; c/o Alectos Therapeutics Inc.,
8999 Nelson Way, Burnaby, British Columbia V5A 4B5
(CA). **MCEACHERN, Ernest J.**; c/o Alectos Therapeutics
Inc., 8999 Nelson Way, Burnaby, British Columbia V5A
4B5 (CA). **SUN, Jianyu**; c/o Alectos Therapeutics Inc.,
8999 Nelson Way, Burnaby, British Columbia V5A 4B5
(CA). **VOCADLO, David J.**; c/o Alectos Therapeutics Inc.,
8999 Nelson Way, Burnaby, British Columbia V5A 4B5
(CA). **ZHOU, Yuanxi**; c/o Alectos Therapeutics Inc., 8999
Nelson Way, Burnaby, British Columbia V5A 4B5 (CA).
ZHU, Yongbao; c/o Alectos Therapeutics Inc., 8999 Nel-
son Way, Burnaby, British Columbia V5A 4B5 (CA).

(74) Agent: **CHATTERJEE, Alakananda**; c/o VanTek IP
LLP, 101-1001 West Broadway, Suite 380, Vancouver,
British Columbia V6H 4E4 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: NON-LYSOSOMAL GLUCOSYL CERAMIDASE INHIBITORS AND USES THEREOF

(57) Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

WO 2021/224865 A1